{"id":266943,"date":"2022-04-27T10:42:35","date_gmt":"2022-04-27T15:42:35","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=266943"},"modified":"2022-04-26T13:28:23","modified_gmt":"2022-04-26T18:28:23","slug":"cms-revises-discriminatory-policy-disabilities","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/","title":{"rendered":"After backlash, CMS revises discriminatory policy against people with disabilities"},"content":{"rendered":"<div style=\"margin-top: 0px; margin-bottom: 0px;\" class=\"sharethis-inline-share-buttons\" ><\/div><p>The Centers for Medicare &amp; Medicaid Services (CMS) released their revised coverage policy for a new Alzheimer\u2019s treatment, Aduhelm, on April 7. Their initial proposal, released <a href=\"https:\/\/archive.liveaction.org\/news\/down-syndrome-barred-alzheimers-drug\/\" target=\"_blank\" rel=\"noopener\">in January<\/a>,\u00a0<a href=\"https:\/\/archive.liveaction.org\/news\/down-syndrome-barred-alzheimers-drug\/\" target=\"_blank\" rel=\"noopener\">excluded people with Down syndrome<\/a> and other intellectual disabilities, a group at high risk of developing Alzheimer\u2019s. In response to backlash from the disability community, the policy was revised.<\/p>\n<p>There has been much controversy over this novel Alzheimer\u2019s therapy, with <a href=\"https:\/\/www.nytimes.com\/2022\/04\/07\/health\/aduhelm-medicare-alzheimers.html\" target=\"_blank\" rel=\"noopener\">concerns<\/a> about its effectiveness, as well as potential side effects. Citing these concerns, CMS has said that it will only cover the cost of Aduhelm for those who are involved in clinical trials. The initial decision not to provide coverage for those with intellectual or developmental disabilities would have created even more barriers to their involvement in trials, continuing a discriminatory practice.<\/p>\n<p>After the exclusion of people with Down syndrome was made public, the disability community quickly mobilized, launching a <a href=\"https:\/\/www.ndss.org\/national-orgs-launch-effort-cms-comment\/\" target=\"_blank\" rel=\"noopener\">joint effort<\/a> to fight back, and ensure equality for all in medicine. &#8220;This collaboration among national Down syndrome organizations is particularly important given how prevalent Alzheimer\u2019s disease is in our community,\u201d a coalition spokesperson said in January. \u201cBy working together, we\u2019re able to bring the expertise of each organization together to mobilize self-advocates, families, caregivers, medical professionals, and the general public to push for inclusion of individuals with Down syndrome in this critical process.&#8221;<\/p>\n<p><strong>READ: <em><a href=\"https:\/\/archive.liveaction.org\/news\/world-health-organization-down-syndrome-birth-defect\/\" target=\"_blank\" rel=\"noopener\">World Health Organization social media post lists Down syndrome as a birth defect to be \u2018prevented\u2019<\/a><\/em><\/strong><\/p>\n<p><center><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/d6GewCpuC30\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center>&nbsp;<\/p>\n<p>Current drugs alleviate symptoms of Alzheimer\u2019s, but there is no treatment to slow the progress of the disease. Biogen\u2019s Aduhelm is the first drug to attempt to treat what is believed to be the cause of Alzheimer\u2019s. People with Alzheimer\u2019s have a build-up of amyloid plaques in their brains, and the creators of Aduhelm believe that targeting this build-up could slow the progress of Alzheimer\u2019s.<\/p>\n<p>In June of 2021, the Federal Drug Administration (FDA) <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug\" target=\"_blank\" rel=\"noopener\">approved<\/a> this new drug for all patients with Alzheimer\u2019s. CMS typically covers drugs approved by the FDA, following any restrictions they give. The FDA has issued no limits on which patients may receive the Aduhelm treatment. Yet, CMS is restricting who will receive coverage for this expensive treatment, which is given through intravenous infusion. Biogen originally priced the treatment at $56,000 per year. When they realized that physicians, insurance companies, and patients were appalled at the high price tag, they lowered the cost to $28,000.<\/p>\n<p>By the time they are in their 60s, about half of those with Down syndrome develop Alzheimer\u2019s.<\/p>\n<p>This is a victory for the Down syndrome community, and a step towards greater equality. Down Syndrome Affiliates in Action, GiGi\u2019s Playhouse Down Syndrome Achievement Centers, the Global Down Syndrome Foundation, the LuMind IDSC Foundation, the National Down Syndrome Congress, and the National Down Syndrome Society published <a href=\"https:\/\/www.disabilityscoop.com\/2022\/04\/18\/feds-reverse-course-on-alzheimers-drug-after-outcry-from-down-syndrome-advocates\/29807\/\" target=\"_blank\" rel=\"noopener\">a joint statement<\/a> in response to the decision, stating, \u201cThe next phase of our collective advocacy must be focused on supporting the inclusion of people with Down syndrome in clinical trials for Alzheimer\u2019s treatments.\u201d<\/p>\n<p style=\"text-align: center;\"><em><strong><a href=\"https:\/\/www.facebook.com\/liveactionnewsonline\/\" target=\"_blank\" rel=\"noopener\">\u201cLike\u201d Live Action News on Facebook<\/a>\u00a0for more pro-life news and commentary!<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Centers for Medicare &amp; Medicaid Services (CMS) released their revised coverage policy for a new Alzheimer\u2019s treatment, Aduhelm, on April 7. Their initial proposal, released in January,\u00a0excluded people with Down syndrome and other intellectual disabilities, a group at high risk of developing Alzheimer\u2019s. In response to backlash from the disability community, the policy was [&hellip;]<\/p>\n","protected":false},"author":678,"featured_media":186246,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false},"categories":[15,3473],"tags":[15726,1631,17080,17072,17073,429,17074,617,17079,17075,15663,17076,17077,17078],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>After backlash, CMS revises discriminatory policy against people with disabilities<\/title>\n<meta name=\"description\" content=\"People with Down syndrome were originally barred by the Centers for Medicare &amp; Medicaid Services from participating in an Alzheimer&#039;s clinical trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"After backlash, CMS revises discriminatory policy against people with disabilities\" \/>\n<meta property=\"og:description\" content=\"People with Down syndrome were originally barred by the Centers for Medicare &amp; Medicaid Services from participating in an Alzheimer&#039;s clinical trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\" \/>\n<meta property=\"og:site_name\" content=\"Live Action News\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/liveaction\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-27T15:42:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-26T18:28:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/archive.liveaction.org\/news\/wp-content\/uploads\/2018\/07\/down-syndrome-son-father-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"650\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Victoria Bergin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@liveaction\" \/>\n<meta name=\"twitter:site\" content=\"@liveaction\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Victoria Bergin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\"},\"author\":{\"name\":\"Victoria Bergin\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/#\/schema\/person\/702a21fd5b687126aa943d2bf0afe5b2\"},\"headline\":\"After backlash, CMS revises discriminatory policy against people with disabilities\",\"datePublished\":\"2022-04-27T15:42:35+00:00\",\"dateModified\":\"2022-04-26T18:28:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\"},\"wordCount\":529,\"publisher\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/#organization\"},\"keywords\":[\"Aduhelm\",\"Alzheimer's\",\"Biogen\",\"Centers for Medicare &amp; Medicaid Services\",\"CMS\",\"Down syndrome\",\"Down Syndrome Affiliates in Action\",\"FDA\",\"Federal Drug Administration\",\"GiGi\u2019s Playhouse Down Syndrome Achievement Centers\",\"National Down Syndrome Society\",\"the Global Down Syndrome Foundation\",\"the LuMind IDSC Foundation\",\"the National Down Syndrome Congress\"],\"articleSection\":[\"Analysis\",\"Newsbreak\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\",\"url\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\",\"name\":\"After backlash, CMS revises discriminatory policy against people with disabilities\",\"isPartOf\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/#website\"},\"datePublished\":\"2022-04-27T15:42:35+00:00\",\"dateModified\":\"2022-04-26T18:28:23+00:00\",\"description\":\"People with Down syndrome were originally barred by the Centers for Medicare & Medicaid Services from participating in an Alzheimer's clinical trial.\",\"breadcrumb\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/archive.liveaction.org\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"After backlash, CMS revises discriminatory policy against people with disabilities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/#website\",\"url\":\"https:\/\/archive.liveaction.org\/news\/\",\"name\":\"Live Action News\",\"description\":\"Covering Human Rights, Abortion, &amp; Pro-Life Issues\",\"publisher\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/archive.liveaction.org\/news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/#organization\",\"name\":\"Live Action\",\"url\":\"https:\/\/archive.liveaction.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/archive.liveaction.org\/news\/wp-content\/uploads\/2016\/06\/Live-Action-Logo-Black.png\",\"contentUrl\":\"https:\/\/archive.liveaction.org\/news\/wp-content\/uploads\/2016\/06\/Live-Action-Logo-Black.png\",\"width\":701,\"height\":710,\"caption\":\"Live Action\"},\"image\":{\"@id\":\"https:\/\/archive.liveaction.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/liveaction\",\"https:\/\/twitter.com\/liveaction\",\"https:\/\/www.instagram.com\/liveactionorg\/\",\"https:\/\/www.pinterest.com\/LiveActionFilms\/\",\"https:\/\/www.youtube.com\/user\/LiveActionFilms\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/#\/schema\/person\/702a21fd5b687126aa943d2bf0afe5b2\",\"name\":\"Victoria Bergin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/archive.liveaction.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/389635f229ec03083e7d134c91500bda?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/389635f229ec03083e7d134c91500bda?s=96&d=mm&r=g\",\"caption\":\"Victoria Bergin\"},\"url\":\"https:\/\/archive.liveaction.org\/news\/author\/victoria-clarizio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"After backlash, CMS revises discriminatory policy against people with disabilities","description":"People with Down syndrome were originally barred by the Centers for Medicare & Medicaid Services from participating in an Alzheimer's clinical trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/","og_locale":"en_US","og_type":"article","og_title":"After backlash, CMS revises discriminatory policy against people with disabilities","og_description":"People with Down syndrome were originally barred by the Centers for Medicare & Medicaid Services from participating in an Alzheimer's clinical trial.","og_url":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/","og_site_name":"Live Action News","article_publisher":"https:\/\/www.facebook.com\/liveaction","article_published_time":"2022-04-27T15:42:35+00:00","article_modified_time":"2022-04-26T18:28:23+00:00","og_image":[{"width":1200,"height":650,"url":"https:\/\/archive.liveaction.org\/news\/wp-content\/uploads\/2018\/07\/down-syndrome-son-father-unsplash.jpg","type":"image\/jpeg"}],"author":"Victoria Bergin","twitter_card":"summary_large_image","twitter_creator":"@liveaction","twitter_site":"@liveaction","twitter_misc":{"Written by":"Victoria Bergin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/#article","isPartOf":{"@id":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/"},"author":{"name":"Victoria Bergin","@id":"https:\/\/archive.liveaction.org\/news\/#\/schema\/person\/702a21fd5b687126aa943d2bf0afe5b2"},"headline":"After backlash, CMS revises discriminatory policy against people with disabilities","datePublished":"2022-04-27T15:42:35+00:00","dateModified":"2022-04-26T18:28:23+00:00","mainEntityOfPage":{"@id":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/"},"wordCount":529,"publisher":{"@id":"https:\/\/archive.liveaction.org\/news\/#organization"},"keywords":["Aduhelm","Alzheimer's","Biogen","Centers for Medicare &amp; Medicaid Services","CMS","Down syndrome","Down Syndrome Affiliates in Action","FDA","Federal Drug Administration","GiGi\u2019s Playhouse Down Syndrome Achievement Centers","National Down Syndrome Society","the Global Down Syndrome Foundation","the LuMind IDSC Foundation","the National Down Syndrome Congress"],"articleSection":["Analysis","Newsbreak"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/","url":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/","name":"After backlash, CMS revises discriminatory policy against people with disabilities","isPartOf":{"@id":"https:\/\/archive.liveaction.org\/news\/#website"},"datePublished":"2022-04-27T15:42:35+00:00","dateModified":"2022-04-26T18:28:23+00:00","description":"People with Down syndrome were originally barred by the Centers for Medicare & Medicaid Services from participating in an Alzheimer's clinical trial.","breadcrumb":{"@id":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/archive.liveaction.org\/news\/cms-revises-discriminatory-policy-disabilities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/archive.liveaction.org\/news\/"},{"@type":"ListItem","position":2,"name":"After backlash, CMS revises discriminatory policy against people with disabilities"}]},{"@type":"WebSite","@id":"https:\/\/archive.liveaction.org\/news\/#website","url":"https:\/\/archive.liveaction.org\/news\/","name":"Live Action News","description":"Covering Human Rights, Abortion, &amp; Pro-Life Issues","publisher":{"@id":"https:\/\/archive.liveaction.org\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/archive.liveaction.org\/news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/archive.liveaction.org\/news\/#organization","name":"Live Action","url":"https:\/\/archive.liveaction.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/archive.liveaction.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/archive.liveaction.org\/news\/wp-content\/uploads\/2016\/06\/Live-Action-Logo-Black.png","contentUrl":"https:\/\/archive.liveaction.org\/news\/wp-content\/uploads\/2016\/06\/Live-Action-Logo-Black.png","width":701,"height":710,"caption":"Live Action"},"image":{"@id":"https:\/\/archive.liveaction.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/liveaction","https:\/\/twitter.com\/liveaction","https:\/\/www.instagram.com\/liveactionorg\/","https:\/\/www.pinterest.com\/LiveActionFilms\/","https:\/\/www.youtube.com\/user\/LiveActionFilms"]},{"@type":"Person","@id":"https:\/\/archive.liveaction.org\/news\/#\/schema\/person\/702a21fd5b687126aa943d2bf0afe5b2","name":"Victoria Bergin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/archive.liveaction.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/389635f229ec03083e7d134c91500bda?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/389635f229ec03083e7d134c91500bda?s=96&d=mm&r=g","caption":"Victoria Bergin"},"url":"https:\/\/archive.liveaction.org\/news\/author\/victoria-clarizio\/"}]}},"_links":{"self":[{"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/posts\/266943"}],"collection":[{"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/users\/678"}],"replies":[{"embeddable":true,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/comments?post=266943"}],"version-history":[{"count":6,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/posts\/266943\/revisions"}],"predecessor-version":[{"id":266970,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/posts\/266943\/revisions\/266970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/media\/186246"}],"wp:attachment":[{"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/media?parent=266943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/categories?post=266943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/archive.liveaction.org\/news\/wp-json\/wp\/v2\/tags?post=266943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}